1887

Chapter 33 : Human Immunodeficiency Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Human Immunodeficiency Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap33-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap33-2.gif

Abstract:

The current designations of specific human immunodeficiency virus (HIV)-1 strains as circulating recombinant form (CRF) versus parental subtypes are subject to change, since putative evolutionary relationships can be confounded by sampling history and high rates of recombination. Disorders of the peripheral nervous system can be classified as distal symmetric polyneuropathy, toxic neuropathy, inflammatory demyelinating polyneuropathy, progressive polyradiculopathy, and mononeuropathy multiplex. The major causes of transmission of HIV, sexual intercourse and injection drug use, represent two extremely strong biological drives. The ultimate goal of chemotherapy of HIV is to thus identify drug regimens that completely inhibit virus replication. Although any function in a genetically efficient organism is a candidate for an inhibitory drug, the currently approved drugs are directed against reverse transcriptase (RT), protease (PR), integrase (IN), and viral entry, with the RT inhibitors being classified as nucleosides or nonnucleosides. The correlation of risk of progression with certain class I human leukocyte antigen (HLA) haplotypes and with the breadth and magnitude of cell-mediated immune responses has prompted interest in therapeutic immunization to enhance these beneficial responses. This approach in general has been aimed at delivering immunogens while the immune system is fully protected by potent antiretroviral chemotherapy and then ascertaining whether a benefit can be discerned after withdrawal of therapy.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Evolutionary relationships between members of the HIV-1 and SIVcpz lineages, based on the phylogenetic analysis of Env protein sequences. The three genetic groups of HIV-1 (M, N, and O) are indicated by brackets on the right, as are related groups of SIVcpz strains from the apparent nonhuman primate source of HIV-1 strains. Five subtypes within group M are also indicated. The scale bar indicates 0.1 amino acid replacement per site. (Modified from reference with permission of the American Association for the Advancement of Science.)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

(A) Structural representation of the envelope glycoprotein complex of HIV-1 interacting with the cellular receptor molecules CD4 and CCR5. The shaded area at the top represents the viral lipid envelope; that at the bottom represents the cellular plasma membrane. The surface subunit gp120 and the transmembrane subunit gp41 of HIV Env form a trimeric complex. The variable loops of the gp120 are not shown and would extend over the outer surface of the complex. (B) Structural representation of the gp120 surface, emphasizing the relationships among the binding sites for CD4 and CCR5, the location of neutralization epitopes, and the protection from antibody responses afforded by the variable loops and by glycosylation. (Panel 1) Surface of the core of gp120, missing most of the major variable loops (V1, V2, V3, and V4). The arrow points to the viral membrane. The interaction sites for CCR5 are lightly shaded; those for CD4 are more darkly shaded. (Panel 2) Conserved neutralization epitopes are indicated: the CD4BS epitopes are darkly shaded, the CD4i epitopes are lightly shaded, and the 2G12 epitope is darkly shaded and toward the right; see the text for definition. (Panel 3) Protection from antibody responses is provided by the V2 and V3 loops, as well as by N-linked glycosylation (sites are shaded). (Panel 4) The neutralizing face of gp120 (light shading) includes the binding sites for CD4 and CCR5; the nonneutralizing face (dark shading) includes the region that interacts with gp41; and the silent face (white) is minimally immunogenic due to glycosylation. (Modified from reference with permission of the American Association for the Advancement of Science.)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Electron micrograph of an HIV-1 virion budding from an infected cell. The viral glycoprotein complexes are barely discernible on the surface of the virion membrane. The electron-dense material just beneath the viral lipid bilayer corresponds to the MA (p17) protein. The conical virion core is composed of the CA (p24) protein. Also within the core are the NC (p7) protein which binds the genomic RNA, the p6 protein required for budding, the accessory protein Vpr, the RT, the IN, and two copies of the genomic RNA. The accessory protein Nef is also virion-associated. (Micrograph courtesy of H. Gelderbloom.)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Genomic organization of HIV-1 and HIV-2. The viral open reading frames are shown; the roles of their gene products are described in the text and in Table 1 . The open reading frames of the and genes are interrupted by an intron. The LTRs found at each end of the fully reverse-transcribed viral DNA are composed of U3, R, and U5 regions; the definitions of their boundaries are described in the text. The major genetic differences between these viruses are the lack of the Vpu open reading frame and the presence of the Vpx open reading frame in HIV-2; these features render HIV-2 more similar to most SIVs than to HIV-1.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Replication cycle of HIV.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

Formation of syncytia during replication of HIV-1 in a culture of T lymphoblastoid cells. In immortalized T-cell lines, the interaction of the viral glycoprotein complex with the cellular receptors CD4 and CXCR4 allows cell-cell fusion and the formation of multinucleated giant cells.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

Cellular dynamics of HIV-1 infection of CD4 T cells. Successive steps in the life cycle of the virus are indicated by horizontal arrows. Transitions between resting (small) and activated (large) CD4 T cells are illustrated by vertical arrows. HIV-1 can infect resting and activated CD4 T cells, but integration of the reverse-transcribed HIV-1 provirus, which is necessary for virus production, occurs only in antigen-activated T cells. Productive infection requires antigen (Ag)-driven activation of recently infected resting CD4 cells or infection of antigen-activated CD4 T cells. Productively infected cells generally die within a few days from cytopathic effects of the infection, but some survive long enough to go back to a resting state, thereby establishing a stable latent reservoir.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

The three stages of disease in a hypothetical case of HIV-1 infection. Solid line, CD4 count; broken line, plasma HIV RNA.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 9
FIGURE 9

Hypothetical plot of plasma virus in a patient who is taking an effective regimen of drugs that block infection of new cells. The plasma virus level drops rapidly in the first 2 weeks of treatment, reflecting the short half-life of the virus in plasma and the short half-life of most of the productively infected cells. These cells appear to be activated CD4 T cells. The decline in plasma virus level shows a second, slower phase, which is due to turnover of cells infected before initiation of therapy. These may be persistently infected macrophages or CD4 T cells that are in a lower state of activation. Alternatively, this RNA could represent the clearance of virions that had accumulated in the germinal centers of lymphoid tissue. The second phase brings the viral load down to below the limit of detection, but the virus persists in reservoirs, including an extremely stable reservoir of latent virus in resting memory CD4 T cells.

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 10
FIGURE 10

(a) Estimated number of AIDS cases and deaths of adults and adolescents with AIDS in the United States and dependent areas during the period from 1985 to 2005. The number of deaths is adjusted for reporting delays. (b) Estimated proportion of persons surviving with AIDS in the United States and dependent areas by year of diagnosis. With new infections continuing unabated and with survival increasing as a result of improving treatment, one consequence is the progressive accumulaton of persons living with HIV infection. (Both figures adapted from the CDC [http://www.cdc.gov/hiv/].)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 11
FIGURE 11

Three-year treatment with indinavir, zidovudine, and lamivudine. (a) Median changes in serum HIV RNA level (Amplicor assay with quantification limit of 500 copies/ml) from baseline. (b) Proportions of patients with serum HIV RNA levels lower than 50 copies/ml (ultradirect assay). (c) Median changes in CD4 cell count from baseline. The number of contributing patients in each trial and at each time point was between 30 and 33. Details regarding the study and analyses are published in reference . (Adapted from reference with permission.)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 12
FIGURE 12

Hypothetical impact of antiviral drug activity on the probability of the emergence of drug resistance. (Reprinted from reference .)

Citation: Guatelli J, Siliciano R, Kuritzkes D, Richman D. 2009. Human Immunodeficiency Virus, p 737-783. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815981.ch33
1. Abecasis, A. B.,, P. Lemey,, N. Vidal,, T. de Oliveira,, M. Peeters,, R. Camacho,, B. Shapiro,, A. Rambaut, and, A. M. Vandamme. 2007. Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype g is a circulating recombinant form. J. Virol. 81:85438551.
2. Aboulafia, D. M.,, and R. T. Mitsuyasu. 1991. Hematologic abnormalities in AIDS. Hematol. Oncol. Clin. North. Am. 5:195214.
3. Accola, M. A.,, B. Strack, and, H. G. Gottlinger. 2000. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74:53955402.
4. Alkhatib, G.,, C. Combadiere,, C. C. Broder,, Y. Feng,, P. E. Kennedy,, P. M. Murphy, and, E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:19551958.
5. Allain, J. P.,, Y. Laurian,, D. A. Paul,, F. Verroust,, M. Leuther,, C. Gazengel,, D. Senn,, M. J. Larrieu, and, C. Bosser. 1987. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N. Engl. J. Med. 317:11141121.
6. Allen, T. M.,, D. H. O’Connor,, P. Jing,, J. L. Dzuris,, B. R. Mothe,, T. U. Vogel,, E. Dunphy,, M. E. Liebl,, C. Emerson,, N. Wilson,, K. J. Kunstman,, X. Wang,, D. B. Allison,, A. L. Hughes,, R. C. Desrosiers,, J. D. Altman,, S. M. Wolinsky,, A. Sette, and, D. I. Watkins. 2000. Tatspecific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386390.
7. Amara, R. R.,, F. Villinger,, J. D. Altman,, S. L. Lydy,, S. P. O’Neil,, S. I. Staprans,, D. C. Montefiori,, Y. Xu,, J. G. Herndon,, L. S. Wyatt,, M. A. Candido,, N. L. Kozyr,, P. L. Earl,, J. M. Smith,, H. L. Ma,, B. D. Grimm,, M. L. Hulsey,, J. Miller,, H. M. McClure,, J. M. McNicholl,, B. Moss, and, H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:6974.
8. Andersen, J. L.,, J. L. DeHart,, E. S. Zimmerman,, O. Ardon,, B. Kim,, G. Jacquot,, S. Benichou, and, V. Planelles. 2006. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog. 2:e127.
9. Arthur, L. O.,, J. W. Bess, Jr.,, R. C. Sowder,, R. E. Benveniste,, D. L. Mann,, J. C. Chermann, and, L. E. Henderson. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:19351938.
10. Arya, S. K.,, C. Guo,, S. F. Josephs, and, F. Wong-Staal. 1985. Transactivator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:6973.
11. Autran, B.,, G. Carcelain,, T. S. Li,, C. Blanc,, D. Mathez,, R. Tubiana,, C. Katlama,, P. Debre, and, J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112116.
12. Autran, B.,, D. Costagliola,, R. Murphy,, N. Wincker,, B. Clotet,, J. Gatell,, R. Tubiana,, S. Staszewski,, B. Walker,, C. Katlama, and the ORVACS Study Group. 2007. Abstr. 14th Conf. Retroviruses Oppor. Infect., abstr. 126LB.
13. Auvert, B.,, D. Taljaard,, E. Lagarde,, J. Sobngwi-Tambekou,, R. Sitta, and, A. Puren. 2005. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2:e298.
14. Ayres, L.,, F. Avillez,, A. Garcia-Benito,, F. Deinhardt,, L. Gurtler,, F. Denis,, G. Leonard,, S. Ranger,, P. Grob, and, H. Joller-Jemelka. 1990. Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2. AIDS 4:131138.
15. Bailey, J. R.,, A. R. Sedaghat,, T. Kieffer,, T. Brennan,, P. K. Lee,, M. Wind-Rotolo,, C. M. Haggerty,, A. R. Kamireddi,, Y. Liu,, J. Lee,, D. Persaud,, J. E. Gallant,, J. Cofrancesco, Jr.,, T. C. Quinn,, C. O. Wilke,, S. C. Ray,, J. D. Siliciano,, R. E. Nettles, and, R. F. Siliciano. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:64416457.
16. Bailey, R. C.,, S. Moses,, C. B. Parker,, K. Agot,, I. Maclean,, J. N. Krieger,, C. F. Williams,, R. T. Campbell, and, J. O. Ndinya-Achola. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369:643656.
17. Barin, F.,, S. M’Boup,, F. Denis,, P. Kanki,, J. S. Allan,, T. H. Lee, and, M. Essex. 1985. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet ii:13871389.
18. Barouch, D. H.,, S. Santra,, J. E. Schmitz,, M. J. Kuroda,, T. M. Fu,, W. Wagner,, M. Bilska,, A. Craiu,, X. X. Zheng,, G. R. Krivulka,, K. Beaudry,, M. A. Lifton,, C. E. Nickerson,, W. L. Trigona,, K. Punt,, D. C. Freed,, L. Guan,, S. Dubey,, D. Casimiro,, A. Simon,, M. E. Davies,, M. Chastain,, T. B. Strom,, R. S. Gelman,, D. C. Montefiori,, M. G. Lewis,, E. A. Emini,, J. W. Shiver, and, N. L. Letvin. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486492.
19. Barré-Sinoussi, F.,, J. C. Chermann,, F. Rey,, M. T. Nugeyre,, S. Chamaret,, J. Gruest,, C. Dauguet,, C. Axler-Blin,, F. Vezinet-Brun,, C. Rouzioux,, W. Rozenbaum, and, L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868871.
20. Bartlett, J. A.,, R. DeMasi,, D. Dawson, and, A. Hill. 1998. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. J. Infect. Dis. 178:18031805.
21. Benichou, S.,, M. Bomsel,, M. Bodeus,, H. Durand,, M. Doute,, F. Letourneur,, J. Camonis, and, R. Benarous. 1994. Physical interaction of the HIV-1 Nef protein with beta-COP, a component of non-clathrin-coated vesicles essential for membrane traffic. J. Biol. Chem. 269:3007330076.
22. Bennett, K. K.,, V. G. DeGruttola,, I. C. Marschner,, D. V. Havlir, and, D. D. Richman. 2002. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 31:2026.
23. Betts, M. R.,, M. C. Nason,, S. M. West,, S. C. De Rosa,, S. A. Migueles,, J. Abraham,, M. M. Lederman,, J. M. Benito,, P. A. Goepfert,, M. Connors,, M. Roederer, and, R. A. Koup. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:47814789.
24. Blanche, S.,, C. Rouzioux,, M. L. Moscato,, F. Veber,, M. J. Mayaux,, C. Jacomet,, J. Tricoire,, A. Deville,, M. Vial, and G. Firtion for the HIV Infection in Newborns French Collaborative Study Group. 1989. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N. Engl. J. Med. 320:16431648.
25. Blankson, J. N.,, J. R. Bailey,, S. Thayil,, H. C. Yang,, K. Lassen,, J. Lai,, S. K. Gandhi,, J. D. Siliciano,, T. M. Williams, and, R. F. Siliciano. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81:25082518.
26. Blankson, J. N.,, D. Finzi,, T. C. Pierson,, B. P. Sabundayo,, K. Chadwick,, J. B. Margolick,, T. C. Quinn, and, R. F. Siliciano. 2000. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 182:16361642.
27. Bosch, M. L.,, P. L. Earl,, K. Fargnoli,, S. Picciafuoco,, F. Giombini,, F. Wong-Staal, and, G. Franchini. 1989. Identification of the fusion peptide of primate immunodeficiency viruses. Science 244:694697.
28. Bozzette, S. A.,, J. A. Mc-Cutchan,, S. A. Spector,, B. Wright, and, D. D. Richman. 1993. A cross-sectional comparison of persons with syncytium- and nonsyncytium-inducing human immunodeficiency virus. J. Infect. Dis. 168:13741379.
29. Branson, B. M.,, H. H. Handsfield,, M. A. Lampe,, R. S. Janssen,, A. W. Taylor,, S. B. Lyss, and, J. E. Clark. 2006. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morb. Mortal. Wkly. Rep. Recomm. Rep. 55:117.
30. Brenchley, J. M.,, D. A. Price,, T. W. Schacker,, T. E. Asher,, G. Silvestri,, S. Rao,, Z. Kazzaz,, E. Bornstein,, O. Lambotte,, D. Altmann,, B. R. Blazar,, B. Rodriguez,, L. Teixeira-Johnson,, A. Landay,, J. N. Martin,, F. M. Hecht,, L. J. Picker,, M. M. Lederman,, S. G. Deeks, and, D. C. Douek. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:13651371.
31. Brenner, B. G.,, M. Roger,, J. P. Routy,, D. Moisi,, M. Ntemgwa,, C. Matte,, J. G. Baril,, R. Thomas,, D. Rouleau,, J. Bruneau,, R. LeBlanc,, M. Legault,, C. Tremblay,, H. Charest, and, M. A. Wainberg. 2007. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195:951959.
32. Brodt, H. R.,, B. S. Kamps,, P. Gute,, B. Knupp,, S. Staszewski, and, E. B. Helm. 1997. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11:17311738.
33. Brun-Vezinet, F.,, M. A. Rey,, C. Katlama,, P. M. Girard,, D. Roulot,, P. Yeni,, L. Lenoble,, F. Clavel,, M. Alizon, and, S. Gadelle. 1987. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet i:128132.
34. Bukrinsky, M. I.,, S. Haggerty,, M. P. Dempsey,, N. Sharova,, A. Adzhubel,, L. Spitz,, P. Lewis,, D. Goldfarb,, M. Emerman, and, M. Stevenson. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666669.
35. Bukrinsky, M. I.,, N. Sharova,, M. P. Dempsey,, T. L. Stanwick,, A. G. Bukrinskaya,, S. Haggerty, and, M. Stevenson. 1992. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA 89:65806584.
36. Bukrinsky, M. I.,, N. Sharova,, T. L. McDonald,, T. Pushkarskaya,, W. G. Tarpley, and, M. Stevenson. 1993. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc. Natl. Acad. Sci. USA 90:61256129.
37. Bukrinsky, M. I.,, T. L. Stanwick,, M. P. Dempsey, and, M. Stevenson. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423427.
38. Burke, D. S.,, J. F. Brundage,, R. R. Redfield,, J. J. Damato,, C. A. Schable,, P. Putman,, R. Visintine, and, H. I. Kim. 1988. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N. Engl. J. Med. 319:961964.
39. Burton, D. R. 1997. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94:1001810023.
40. Busch, M. P.,, L. L. Lee,, G. A. Satten,, D. R. Henrard,, H. Farzadegan,, K. E. Nelson,, S. Read,, R. Y. Dodd, and, L. R. Petersen. 1995. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion (Paris) 35:9197.
41. Bushman, F. D.,, T. Fujiwara, and, R. Craigie. 1990. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249:15551558.
42. Calarese, D. A.,, H. K. Lee,, C. Y. Huang,, M. D. Best,, R. D. Astronomo,, R. L. Stanfield,, H. Katinger,, D. R. Burton,, C. H. Wong, and, I. A. Wilson. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. USA 102:1337213377.
43. Cameron, P. U.,, P. S. Freudenthal,, J. M. Barker,, S. Gezelter,, K. Inaba, and, R. M. Steinman. 1992. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257:383387.
44. Cao, J.,, I. W. Park,, A. Cooper, and, J. Sodroski. 1996. Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J. Virol. 70:13401354.
45. Cao, Y.,, L. Qin,, L. Zhang,, J. Safrit, and, D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201208.
46. Carrington, M.,, G. W. Nelson,, M. P. Martin,, T. Kissner,, D. Vlahov,, J. J. Goedert,, R. Kaslow,, S. Buchbinder,, K. Hoots, and, S. J. O’Brien. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:17481752.
47. Centers for Disease Control and Prevention. 1988. Update: serologic testing for antibody to human immunodeficiency virus. Morb. Mortal. Wkly. Rep. 36:833845.
48. Centers for Disease Control and Prevention. 1989. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. Morb. Mortal. Wkly. Rep. 38:17.
49. Centers for Disease Control and Prevention. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb. Mortal. Wkly. Rep. 41:119.
50. Centers for Disease Control and Prevention. 2001. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Morb. Mortal. Wkly. Rep. 50:152.
51. Chan, D. C.,, D. Fass,, J. M. Berger, and, P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263273.
52. Chang, Y.,, E. Cesarman,, M. S. Pessin,, F. Lee,, J. Culpepper,, D. M. Knowles, and, P. S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:18651869.
53. Charneau, P.,, M. Alizon, and, F. Clavel. 1992. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66:28142820.
54. Chertova, E.,, J. J. Bess, Jr.,, B. J. Crise,, R. C. Sowder II,, T. M. Schaden,, J. M. Hilburn,, J. A. Hoxie,, R. E. Benveniste,, J. D. Lifson,, L. E. Henderson, and, L. O. Arthur. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:53155325.
55. Chertova, E.,, O. Chertov,, L. V. Coren,, J. D. Roser,, C. M. Trubey,, J. W. Bess, Jr.,, R. C. Sowder II,, E. Barsov,, B. L. Hood,, R. J. Fisher,, K. Nagashima,, T. P. Conrads,, T. D. Veenstra,, J. D. Lifson, and, D. E. Ott. 2006. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J. Virol. 80:90399052.
56. Chesebro, B.,, K. Wehrly,, J. Nishio, and, S. Perryman. 1992. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:65476554.
57. Chiu, Y. L.,, V. B. Soros,, J. F. Kreisberg,, K. Stopak,, W. Yonemoto, and, W. C. Greene. 2005. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435:108114.
58. Choe, H.,, M. Farzan,, Y. Sun,, N. Sullivan,, B. Rollins,, P. D. Ponath,, L. Wu,, C. R. Mackay,, G. LaRosa,, W. Newman,, N. Gerard,, C. Gerard, and, J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:11351148.
59. Chun, T. W.,, L. Carruth,, D. Finzi,, X. Shen,, J. A. DiGiuseppe,, H. Taylor,, M. Hermankova,, K. Chadwick,, J. Margolick,, T. C. Quinn,, Y. H. Kuo,, R. Brookmeyer,, M. A. Zeiger,, P. Barditch-Crovo, and, R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183188.
60. Chun, T. W.,, D. Engel,, M. M. Berrey,, T. Shea,, L. Corey, and, A. S. Fauci. 1998. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95:88698873.
61. Chun, T. W.,, D. Finzi,, J. Margolick,, K. Chadwick,, D. Schwartz, and, R. F. Siliciano. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:12841290.
62. Chun, T. W.,, L. Stuyver,, S. B. Mizell,, L. A. Ehler,, J. A. Mican,, M. Baseler,, A. L. Lloyd,, M. A. Nowak, and, A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:1319313197.
63. Ciesielski, C. A.,, D. W. Marianos,, G. Schochetman,, J. J. Witte, and, H. W. Jaffe. 1994. The 1990 Florida dental investigation. The press and the science. Ann. Intern. Med. 121:886888.
64. Cocchi, F.,, A. L. DeVico,, A. Garzino-Demo,, S. K. Arya,, R. C. Gallo, and, P. Lusso. 1995. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:18111815.
65. Collins, K. L.,, B. K. Chen,, S. A. Kalams,, B. D. Walker, and, D. Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397401.
66. Connor, E. M.,, R. S. Sperling,, R. Gelber,, P. Kiselev,, G. Scott,, M. J. O’Sullivan,, R. VanDyke,, M. Bey,, W. Shearer, and, R. L. Jacobson for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:11731180.
67. Connor, R. I.,, H. Mohri,, Y. Cao, and, D. D. Ho. 1993. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67:17721777.
68. Coombs, R. W.,, S. L. Welles,, C. Hooper,, P. S. Reichelderfer,, R. T. D’Aquila,, A. J. Japour,, V. A. Johnson,, D. R. Kuritzkes,, D. D. Richman,, S. Kwok,, J. Todd,, J. B. Jackson,, V. DeGruttola,, C. S. Crumpacker, and J. Kahn for the AIDS Clinical Trials Group (ACTG) 116B/117 Study Team and the ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704712.
69. Coopman, S. A.,, R. A. Johnson,, R. Platt, and, R. S. Stern. 1993. Cutaneous disease and drug reactions in HIV infection. N. Engl. J. Med. 328:16701674.
70. Coovadia, H. M.,, N. C. Rollins,, R. M. Bland,, K. Little,, A. Coutsoudis,, M. L. Bennish, and, M. L. Newell. 2007. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369:11071116.
71. Corbett, E. L.,, B. Marston,, G. J. Churchyard, and, K. M. De Cock. 2006. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of anti-retroviral treatment. Lancet 367:926937.
72. Cozzi Lepri A.,, T. L. Katzenstein,, H. Ullum,, A. N. Phillips,, P. Skinhoj,, J. Gerstoft, and, B. K. Pedersen. 1998. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 12:16391643.
73. Craig, H. M.,, M. W. Pandori, and, J. C. Guatelli. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. USA 95:1122911234.
74. Daar, E. S.,, S. Little,, J. Pitt,, J. Santangelo,, P. Ho,, N. Harawa,, P. Kerndt,, J. V. Glorgi,, J. Bai,, P. Gaut,, D. D. Richman,, S. Mandel, and S. Nichols for the Los Angeles County Primary HIV Infection Recruitment Network. 2001. Diagnosis of primary HIV-1 infection. Ann. Intern. Med. 134:2529.
75. Dalgleish, A. G.,, P. C. Beverley,, P. R. Clapham,, D. H. Crawford,, M. F. Greaves, and, R. A. Weiss. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763767.
76. Davies, J. F.,, Z. Hostomska,, Z. Hostomsky,, S. R. Jordan, and, D. A. Matthews. 1991. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252:8895.
77. Day, C. L.,, D. E. Kaufmann,, P. Kiepiela,, J. A. Brown,, E. S. Moodley,, S. Reddy,, E. W. Mackey,, J. D. Miller,, A. J. Leslie,, C. DePierres,, Z. Mncube,, J. Duraiswamy,, B. Zhu,, Q. Eichbaum,, M. Altfeld,, E. J. Wherry,, H. M. Coovadia,, P. J. Goulder,, P. Klenerman,, R. Ahmed,, G. J. Freeman, and, B. D. Walker. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350354.
78. Deacon, N. J.,, A. Tsykin,, A. Solomon,, K. Smith,, M. Ludford-Menting,, D. J. Hooker,, D. A. McPhee,, A. L. Greenway,, A. Ellett,, C. Chatfield,, V. A. Lawson,, S. Crowe,, A. Maerz,, S. Sonza,, J. Learmont,, J. S. Sullivan,, A. Cunningham,, D. Dwyer,, D. Dowton, and, J. Mills. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988991.
79. De Cock, K. M.,, and H. A. Weiss. 2000. The global epidemiology of AIDS. Trop. Med. Int. Health 5:A3A9.
80. De Gruttola, V.,, L. Dix,, R. D’Aquila,, D. Holder,, A. Phillips,, M. Ait-Khaled,, J. Baxter,, P. Clevenbergh,, S. Hammer,, R. Harrigan,, D. Katzenstein,, R. Lanier,, M. Miller,, M. Para,, S. Yerly,, A. Zolopa,, J. Murray,, A. Pa-tick,, V. Miller,, S. Castillo,, L. Pedneault, and, J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther. 5:4148.
81. DeHart, J. L.,, E. S. Zimmerman,, O. Ardon,, C. M. Monteiro-Filho,, E. R. Arganaraz, and, V. Planelles. 2007. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol. J. 4:57.
82. Delaney, K. P.,, B. M. Branson,, A. Uniyal,, P. R. Kerndt,, P. A. Keenan,, K. Jafa,, A. D. Gardner,, D. J. Jamieson, and, M. Bulterys. 2006. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 20:16551660.
83. Deschambeault, J.,, J. P. Lalonde,, G. Cervantes-Acosta,, R. Lodge,, E. A. Cohen, and, G. Lemay. 1999. Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. J. Virol. 73:50105017.
84. Desrosiers, R. C.,, J. D. Lifson,, J. S. Gibbs,, S. C. Czajak,, A. Y. Howe,, L. O. Arthur, and, R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:14311437.
85. Dion, M. L.,, J. F. Poulin,, R. Bordi,, M. Sylvestre,, R. Corsini,, N. Kettaf,, A. Dalloul,, M. R. Boulassel,, P. Debre,, J. P. Routy,, Z. Grossman,, R. P. Sekaly, and, R. Cheynier. 2004. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 21:757768.
86. Dittmer, U.,, D. M. Brooks, and, K. J. Hasenkrug. 1999. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat. Med. 5:189193.
87. Dorenbaum, A. 2001. Abstr. 8th Conf. Retroviruses Oppor. Infect., abstr. LB7.
88. Dorfman, T.,, F. Mammano,, W. A. Haseltine, and, H. G. Gottlinger. 1994. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 68:16891696.
89. Dormant, D.,, J. Livartowski,, S. Chararet,, D. Guetard,, D. Henin,, R. Levagueresse,, P. F. van de Moortelle,, B. Larke,, P. Gourmelon,, R. Vazeaux,, H. Metivier,, J. Flageat,, L. Court,, J. J. Hauw, and, L. Montagnier. 1989. HIV-2 in rhesus monkeys: serological, virological, and clinical results. Intervirology 30:5965.
90. Dornadula, G.,, H. Zhang,, B. VanUitert,, J. Stern,, L. Livornese, Jr.,, M. J. Ingerman,, J. Witek,, R. J. Kedanis,, J. Natkin,, J. DeSimone, and, R. J. Pomerantz. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:16271632.
91. Douek, D. C.,, R. D. McFarland,, P. H. Keiser,, E. A. Gage,, J. M. Massey,, B. F. Haynes,, M. A. Polis,, A. T. Haase,, M. B. Feinberg,, J. L. Sullivan,, B. D. Jamieson,, J. A. Zack,, L. J. Picker, and, R. A. Koup. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690695.
92. Druce, J. D.,, D. Jardine,, S. A. Locarnini, and, C. J. Birch. 1995. Susceptibility of HIV to inactivation by disinfectants and ultraviolet light. J. Hosp. Infect. 30:167180.
93. Dunn, D. T.,, C. D. Brandt,, A. Krivine,, S. A. Cassol,, P. Roques,, W. Borkowsky,, A. De Rossi,, E. Denamur,, A. Ehrnst, and, C. Loveday. 1995. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intrapartum transmission. AIDS 9:F7F11.
94. Durant, J.,, P. Clevenbergh,, P. Halfon,, P. Delgiudice,, S. Porsin,, P. Simonet,, N. Montagne,, C. A. Boucher,, J. M. Schapiro, and, P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:21952199.
95. Edinger, A. L.,, J. L. Mankowski,, B. J. Doranz,, B. J. Margulies,, B. Lee,, J. Rucker,, M. Sharron,, T. L. Hoffman,, J. F. Berson,, M. C. Zink,, V. M. Hirsch,, J. E. Clements, and, R. W. Doms. 1997. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc. Natl. Acad. Sci. USA 94:1474214747.
96. Elias, C. J.,, and L. L. Heise. 1994. Challenges for the development of female-controlled vaginal microbicides. AIDS 8:19.
97. Emerman, M.,, and M. H. Malim. 1998. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280:18801884.
98. Epstein, L. G.,, C. Kuiken,, B. M. Blumberg,, S. Hartman,, L. R. Sharer,, M. Clement, and, J. Goudsmit. 1991. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology 180:583590.
99. Esnault, C.,, O. Heidmann,, F. Delebecque,, M. Dewannieux,, D. Ribet,, A. J. Hance,, T. Heidmann, and, O. Schwartz. 2005. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433:430433.
100. European Collaborative Study. 1991. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 337:253260.
101. European Collaborative Study. 1994. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 94:815819.
102. Ewart, G. D.,, T. Sutherland,, P. W. Gage, and, G. B. Cox. 1996. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70:71087115.
103. Fahey, J. L.,, J. M. Taylor,, R. Detels,, B. Hofmann,, R. Melmed,, P. Nishanian, and, J. V. Giorgi. 1990. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322:166172.
104. Fahrbach, K. M.,, S. M. Barry,, S. Ayehunie,, S. Lamore,, M. Klausner, and, T. J. Hope. 2007. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J. Virol. 81:68586868.
105. Farnet, C. M.,, and F. D. Bushman. 1997. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 88:483492.
106. Farnet, C. M.,, and F. D. Bushman. 1996. HIV cDNA integration: molecular biology and inhibitor development. AIDS 10(Suppl. A):S3S11.
107. Farnet, C. M.,, and W. A. Haseltine. 1991. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J. Virol. 65:19101915.
108. Feng, Y.,, C. C. Broder,, P. E. Kennedy, and, E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872877.
109. Fiala, M.,, D. J. Looney,, M. Stins,, D. D. Way,, L. Zhang,, X. Gan,, F. Chiappelli,, E. S. Schweitzer,, P. Shapshak,, M. Weinand,, M. C. Graves,, M. Witte, and, K. S. Kim. 1997. TNF-α opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol. Med. 3:553564.
110. Filippi, C. G.,, G. Sze,, S. J. Farber,, M. Shahmanesh, and, P. A. Selwyn. 1998. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 206:491498.
111. Finkel, T. H.,, G. Tudor-Williams,, N. K. Banda,, M. F. Cotton,, T. Curiel,, C. Monks,, T. W. Baba,, R. M. Ruprecht, and, A. Kupfer. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:129134.
112. Finzi, D.,, J. Blankson,, J. D. Siliciano,, J. B. Margolick,, K. Chadwick,, T. Pierson,, K. Smith,, J. Lisziewicz,, F. Lori,, C. Flexner,, T. C. Quinn,, R. E. Chaisson,, E. Rosenberg,, B. Walker,, S. Gange,, J. Gallant, and, R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512517.
113. Finzi, D.,, M. Hermankova,, T. Pierson,, L. M. Carruth,, C. Buck,, R. E. Chaisson,, T. C. Quinn,, K. Chadwick,, J. Margolick,, R. Brookmeyer,, J. Gallant,, M. Markowitz,, D. D. Ho,, D. D. Richman, and, R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:12951300.
114. Finzi, D.,, and R. F. Siliciano. 1998. Viral dynamics in HIV-1 infection. Cell 93:665671.
115. Fletcher, T. M., III,, B. Brichacek,, N. Sharova,, M. A. Newman,, G. Stivahtis,, P. M. Sharp,, M. Emerman,, B. H. Hahn, and, M. Stevenson. 1996. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J. 15:61556165.
116. Fornerod, M.,, M. Ohno,, M. Yoshida, and, I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:10511060.
117. Fortin, J. F.,, R. Cantin,, G. Lamontagne, and, M. Tremblay. 1997. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 71:35883596.
118. French, M. A.,, P. Price, and, S. F. Stone. 2004. Immune restoration disease after antiretroviral therapy. AIDS 18:16151627.
119. Frost, S. D.,, T. Wrin,, D. M. Smith,, S. L. Kosakovsky Pond,, Y. Liu,, E. Paxinos,, C. Chappey,, J. Galovich,, J. Beauchaine,, C. J. Petropoulos,, S. J. Little, and, D. D. Richman. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102:1851418519.
120. Fujikawa, L. S.,, S. Z. Salahuddin,, A. G. Palestine,, H. Masur,, R. B. Nussenblatt, and, R. C. Gallo. 1985. Isolation of human T-lymphotropic virus type III from the tears of a patient with the acquired immunodeficiency syndrome. Lancet ii:529530.
121. Fultz, P. N.,, H. M. McClure,, R. B. Swenson,, C. R. McGrath,, A. Brodie,, J. P. Getchell,, F. C. Jensen,, D. C. Anderson,, J. R. Broderson, and, D. P. Francis. 1986. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J. Virol. 58:116124.
122. Furtado, M. R.,, D. S. Callaway,, J. P. Phair,, K. J. Kunstman,, J. L. Stanton,, C. A. Macken,, A. S. Perelson, and, S. M. Wolinsky. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:16141622.
123. Gabuzda, D. H.,, K. Lawrence,, E. Langhoff,, E. Terwilliger,, T. Dorfman,, W. A. Haseltine, and, J. Sodroski. 1992. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66:64896495.
124. Gaines, H.,, M. von Sydow,, A. Sonnerborg,, J. Albert,, J. Czajkowski,, P. O. Pehrson,, F. Chiodi,, L. Moberg,, E. M. Fenyo, and, B. Asjo. 1987. Antibody response in primary human immunodeficiency virus infection. Lancet i:12491253.
125. Galli, L.,, M. de Martino,, P. A. Tovo,, C. Gabiano,, M. Zappa,, C. Giaquinto,, S. Tulisso,, A. Vierucci,, M. Guerra, and P. Marchisio for the Italian Register for HIV Infection in Children. 1995. Onset of clinical signs in children with HIV-1 perinatal infection. AIDS 9:455461.
126. Gao, F.,, E. Bailes,, D. L. Robertson,, Y. Chen,, C. M. Rodenburg,, S. F. Michael,, L. B. Cummins,, L. O. Arthur,, M. Peeters,, G. M. Shaw,, P. M. Sharp, and, B. H. Hahn. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436441.
127. Garcia, J. V.,, and A. D. Miller. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508511.
128. Gartner, S.,, P. Markovits,, D. M. Markovitz,, M. H. Kaplan,, R. C. Gallo, and, M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215219.
129. Gayle, H. 2000. An overview of the global HIV/AIDS epidemic, with a focus on the United States. AIDS 14(Suppl. 2):S8S17.
130. Gaynor, R. 1992. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 6:347363.
131. Geijtenbeek, T. B.,, D. S. Kwon,, R. Torensma,, S. J. van Vliet,, G. C. van Duijnhoven,, J. Middel,, I. L. Cornelissen,, H. S. Nottet,, V. N. Kewal-Ramani,, D. R. Littman,, C. G. Figdor, and, Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587597.
132. Gerberding, J. L.,, C. E. Bryant-LeBlanc,, K. Nelson,, A. R. Moss,, D. Osmond,, H. F. Chambers,, J. R. Carlson,, W. L. Drew,, J. A. Levy, and, M. A. Sande. 1987. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J. Infect. Dis. 156:18.
133. Gilbert, M. T.,, A. Rambaut,, G. Wlasiuk,, T. J. Spira,, A. E. Pitchenik, and, M. Worobey. 2007. The emergence of HIV/AIDS in the Americas and beyond. Proc. Natl. Acad. Sci. USA 104:1856618570.
134. Gorelick, R. J.,, S. M. Nigida, Jr.,, J. W. Bess, Jr.,, L. O. Arthur,, L. E. Henderson, and, A. Rein. 1990. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol. 64:32073211.
135. Gotch, F. M.,, D. F. Nixon,, N. Alp,, A. J. McMichael, and, L. K. Borysiewicz. 1990. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol. 2:707712.
136. Gottlieb, M. S.,, R. Schroff,, H. M. Schanker,, J. D. Weisman,, P. T. Fan,, R. A. Wolf, and, A. Saxon. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305:14251431.
137. Goulder, P. J.,, C. Brander,, Y. Tang,, C. Tremblay,, R. A. Colbert,, M. M. Addo,, E. S. Rosenberg,, T. Nguyen,, R. Allen,, A. Trocha,, M. Altfeld,, S. He,, M. Bunce,, R. Funkhouser,, S. I. Pelton,, S. K. Burchett,, K. McIntosh,, B. T. Korber, and, B. D. Walker. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412:334338.
138. Grabar, S.,, M. Le,, V. C. Goujard,, C. Leport,, M. D. Kazatchkine,, D. Costagliola, and, L. Weiss. 2000. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133:401410.
139. Gray, R. H.,, G. Kigozi,, D. Serwadda,, F. Makumbi,, S. Watya,, F. Nalugoda,, N. Kiwanuka,, L. H. Moulton,, M. A. Chaudhary,, M. Z. Chen,, N. K. Sewankambo,, F. Wabwire-Mangen,, M. C. Bacon,, C. F. Williams,, P. Opendi,, S. J. Reynolds,, O. Laeyendecker,, T. C. Quinn, and, M. J. Wawer. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369:657666.
140. Greenblatt, R. M.,, S. A. Lukehart,, F. A. Plummer,, T. C. Quinn,, C. W. Critchlow,, R. L. Ashley,, L. J. D’Costa,, J. O. Ndinya-Achola,, L. Corey, and, A. R. Ronald. 1988. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2:4750.
141. Groopman, J. E.,, S. Z. Salahuddin,, M. G. Sarngadharan,, P. D. Markham,, M. Gonda,, A. Sliski, and, R. C. Gallo. 1984. HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science 226:447449.
142. Grulich, A. E.,, M. T. van Leeuwen,, M. O. Falster, and, C. M. Vajdic. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:5967.
143. Grunfeld, C.,, and D. P. Kotler. 1992. Wasting in the acquired immunodeficiency syndrome. Semin. Liver Dis. 12:175187.
144. Gulick, R. M.,, J. W. Mellors,, D. Havlir,, J. J. Eron,, C. Gonzalez,, D. McMahon,, D. D. Richman,, F. T. Valentine,, L. Jonas,, A. Meibohm,, E. A. Emini, and, J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734739.
145. Reference deleted.
146. Guy, B.,, M. P. Kieny,, Y. Riviere,, P. C. Le,, K. Dott,, M. Girard,, L. Montagnier, and, J. P. Lecocq. 1987. HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 330:266269.
147. Haase, A. T. 1986. Pathogenesis of lentivirus infections. Nature 322:130136.
148. Haase, A. T. 1999. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17:625656.
149. Haase, A. T.,, K. Henry,, M. Zupancic,, G. Sedgewick,, R. A. Faust,, H. Melroe,, W. Cavert,, K. Gebhard,, K. Staskus,, Z. Q. Zhang,, P. J. Dailey,, H. H. Balfour, Jr.,, A. Erice, and, A. S. Perelson. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985989.
150. Hahn, B. H.,, G. M. Shaw,, K. M. De Cock, and, P. M. Sharp. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607614.
151. Hammer, S. M.,, M. S. Saag,, M. Schechter,, J. S. Montaner,, R. T. Schooley,, D. M. Jacobsen,, M. A. Thompson,, C. C. Carpenter,, M. A. Fischl,, B. G. Gazzard,, J. M. Gatell,, M. S. Hirsch,, D. A. Katzenstein,, D. D. Richman,, S. Vella,, P. G. Yeni, and, P. A. Volberding. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society—USA panel. JAMA 296:827843.